However, as the studies were conducted at the very dawn of TNF inhibitors therapy for the treatment of rheumatic diseases, protocols for LTBI screening and treatment were not yet well established, and the risk of reactivation of granulomatous disease was consequently higher, with a greater number of cases in their populations. Here, TNF is linked to rheumatic disorder.